1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Sunshine Heart Endures Slow Enrollment For C-Pulse Heart Failure Device

Sunshine Heart CEO David Rosa details the challenges of enrolling patients in a trial targeted specifically at patients with Class III heart failure. The firm hopes the study of the C-Pulse heart assist system can be completed by early 2016, but is also cooking up a plan to start submitting data to FDA before enrollment finishes.

Sunshine Heart Inc. is persevering against patient-enrollment challenges to complete the COUNTER HF

pivotal U.S. trial of its unique C-Pulse heart-assist device for advanced heart failure and no other viable options.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Daye Breaks Into Hormone Self-Testing, Adds New Data To Extensive Gynecology Database

 
• By Natasha Barrow

Daye is launching an at-home reproductive hormone testing service in the UK, utilizing a painless upper arm blood collection method. The product’s UKAS lab accreditation helps build credibility with healthcare providers.

Roche Eyes 2026 FDA Nod After CE Mark For pTau181 Test To Boost Global Alzheimer’s Diagnosis

 
• By Shubham Singh

The Elecsys pTau181 test, which requires only a blood sample, provides a less invasive alternative to cerebral spinal fluid procedures. A negative result could rule out Alzheimer’s and help patients avoid further testing with CSF or PET scans.

HistoSonics Sells Majority Stake To Investor Syndicate In Deal Valued At $2.25Bn

 
• By Marion Webb

HistoSonics’ CEO Michael Blue describes the deal as a win-win for all stakeholders and plans to use the money to expand clinical indications, as well as the global reach, for its Edison system.